Universal cancer peptides derived from telomerase
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jun 6, 2017
Issued Date -
N/A
app pub date -
Mar 7, 2013
filing date -
Mar 16, 2012
priority date (Note) -
In Force
status (Latency Note)
Importance
Loading Importance Indicators... 
Abstract
The invention relates to a peptide of 15 to 20 amino acids deriving from TERT protein, which peptide is capable of (i) binding to HLA class II and (ii) stimulating a CD4 Th response. These universal cancer peptides are especially useful in anti-tumor immunotherapy and immunomonitoring.
First Claim
Other Claims data not available
Family
Loading Family data...
International Classification(s)
- 2013 Application Filing Year
- A61K Class
- 12711 Applications Filed
- 11051 Patents Issued To-Date
- 86.95 % Issued To-Date
Cited Art Landscape
Patent Citation Ranking
- 0 Citation Count
- A61K Class
- 0 % this patent is cited more than
- 8 Age
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|---|---|---|---|
| 7.5 Year Payment | $3600.00 | $1800.00 | $900.00 | Dec 6, 2024 |
| 11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Dec 6, 2028 |
